A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
This randomized, blinded, parallel arm study evaluated the efficacy and safety of tocilizumab
(RoActemra/Actemra) versus adalimumab as monotherapy in patients with rheumatoid arthritis
who are intolerant of methotrexate or where continued treatment with methotrexate was
considered inappropriate. Patients were randomized to receive either tocilizumab 8 mg/kg
intravenously (iv) every 4 weeks plus placebo subcutaneously (sc) every 2 weeks, or
adalimumab 40 mg sc every 2 weeks plus placebo iv every 4 weeks. Treatment was anticipated to
last 24 weeks. With regard to the blind, the study nurse was unblinded due to the nature of
the treatment administration, but the investigator and the patient remained blinded.